Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

Дата публикации: 28-05-2026 04:05:03

WALTHAM, Mass. and BOULDER, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)	0	12.6	30-06-2026
2	U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	0	11.68	28-04-2026
3	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	0	11.63	01-06-2026
4	U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir	0	14.72	29-04-2026
5	U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma	0	6.44	13-07-2026
6	New Drug Application for Neladalkib in TKI Pre-Treated Advanced ALK-Positive NSCLC Accepted for Filing with Priority Review by the FDA	0	17.4	27-05-2026
7	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
8	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD	0	15.69	28-05-2026
9	Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to Treat Primary Biliary Cholangitis (PBC) Granted Priority Review by the US FDA	0	11.94	28-05-2026
10	Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension	0	10.41	23-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.76. Источник: www.drugs.com.